Seroatlas · Human Serome Atlas

TACSTD2

Tumor-associated calcium signal transducer 2

Also known as: EGP-1, GA733-1, M1S1, TACD2_HUMAN, TROP2

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P09758
Gene
TACSTD2
Ensembl
ENSG00000184292
Chromosome
1
Canonical length
323 aa
Protein class
Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins
Subcellular location
Nucleoli,Vesicles,Plasma membrane

OverviewNCBI Gene

This intronless gene encodes a carcinoma-associated antigen. This antigen is a cell surface receptor that transduces calcium signals. Mutations of this gene have been associated with gelatinous drop-like corneal dystrophy.[provided by RefSeq, Dec 2009]

Canonical amino-acid sequenceUniProt

323 residues, UniProt reviewed canonical sequence.

>P09758|TACSTD2
     1  MARGPGLAPP PLRLPLLLLV LAAVTGHTAA QDNCTCPTNK MTVCSPDGPG GRCQCRALGS
    61  GMAVDCSTLT SKCLLLKARM SAPKNARTLV RPSEHALVDN DGLYDPDCDP EGRFKARQCN
   121  QTSVCWCVNS VGVRRTDKGD LSLRCDELVR THHILIDLRH RPTAGAFNHS DLDAELRRLF
   181  RERYRLHPKF VAAVHYEQPT IQIELRQNTS QKAAGDVDIG DAAYYFERDI KGESLFQGRG
   241  GLDLRVRGEP LQVERTLIYY LDEIPPKFSM KRLTAGLIAV IVVVVVALVA GMAVLVITNR
   301  RKSGKYKKVE IKELGELRKE PSL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TACSTD2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
1
Mean surface accessibility (rSASA)
0.39
Highest tissue expression
1,245 nTPM

Expression across tissuesHPA

Tissue

  • esophagus: 1,245 nTPM
  • salivary gland: 585 nTPM
  • skin: 555 nTPM
  • vagina: 488 nTPM
  • cervix: 366 nTPM
  • urinary bladder: 219 nTPM

Single-cell type

  • esophageal apical cells: 17,506 nCPM
  • epididymal basal cells: 7,482 nCPM
  • esophageal suprabasal cells: 5,347 nCPM
  • ocular epithelial cells: 3,288 nCPM
  • suprabasal keratinocytes: 2,163 nCPM
  • esophageal basal cells: 2,064 nCPM

Immune cell

  • eosinophil: 15 nTPM
  • myeloid DC: 4.3 nTPM
  • classical monocyte: 4.2 nTPM
  • neutrophil: 2.9 nTPM
  • total PBMC: 1.8 nTPM
  • intermediate monocyte: 0.1 nTPM

Brain region

  • choroid plexus: 3.9 nTPM
  • white matter: 1.1 nTPM
  • basal ganglia: 0.6 nTPM
  • cerebral cortex: 0.5 nTPM
  • hypothalamus: 0.5 nTPM
  • thalamus: 0.5 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about TACSTD2.

Disease | AllUniProt

Conditions TACSTD2 is implicated in, by any mechanism.

  • Corneal dystrophy, gelatinous drop-like (GDLD) MIM:204870

Disease | GeneticClinVar

11 pathogenic / likely-pathogenic of 119 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

  • Gelatinous droplike corneal dystrophy

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.53
gnomAD pLI
0
gnomAD missense Z
0.56
DepMap mean gene effect
-0.03
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TACSTD2 as an antibody target. Whether an autoantibody or antibody against TACSTD2 could matter depends on whether native TACSTD2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TACSTD2 is annotated at the cell surface, where native TACSTD2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label TACSTD2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/TACSTD2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...